Piperacillin-tazobactam is one of the most common causes of drug-induced immune hemolytic anemia (DIIHA) and is frequently utilized, especially in patients with cystic fibrosis (CF). Here, we report a case of life-threatening piperacillin-tazobactam-associated DIIHA in a 30-year-old woman with CF and propose management recommendations for piperacillin-tazobactam-associated DIIHA in CF patients.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5715418 | PMC |
| http://dx.doi.org/10.1002/ccr3.1256 | DOI Listing |
Publication Analysis
Top Keywords
cystic fibrosis
8
piperacillin-tazobactam-associated diiha
8
severe piperacillin-tazobactam-induced
4
piperacillin-tazobactam-induced hemolysis
4
hemolysis cystic
4
fibrosis patient
4
patient piperacillin-tazobactam
4
piperacillin-tazobactam common
4
common drug-induced
4
drug-induced immune
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!